Exploration of shared pathogenic factors and causative genes in early-stage endometrial cancer and osteoarthritis
- PMID: 40594157
- PMCID: PMC12216496
- DOI: 10.1038/s41598-025-04470-x
Exploration of shared pathogenic factors and causative genes in early-stage endometrial cancer and osteoarthritis
Abstract
Osteoarthritis (OA) has been implicated in the development and progression of early-stage endometrial cancer (EC), suggesting shared pathogenic factors between the two diseases. This study aimed to investigate the causal relationship between OA and EC and to identify causative genes common to both early-stage EC and OA. A Two-sample Mendelian randomization (MR) analysis was first performed to assess the causal relationship between OA and EC. Differentially expressed genes associated with early-stage EC and OA were identified using the limma package. Overlapping genes were extracted to determine common causative genes, followed by enrichment analysis. The causal relationship between these genes and EC was verified through Mendelian randomization (MR) of drug targets. Genes with diagnostic value were identified using multiple machine learning algorithms to construct EC prediction models and evaluate their performance. Additionally, the study examined the correlation between diagnostic-value genes and immune cell infiltration. IVW analysis indicated that OA was a high-risk factor for the development of EC (P < 0.05). Seven common causative genes (CDKN2A, DDA1, LRRC42, POLB, ADCYAP1R1, DNMT3A, and GLRX5) were identified for OA and EC, showing significant enrichment in related pathways such as heterochromatin. MR analysis of drug targets revealed that CDKN2A, DDA1, LRRC42, and POLB had diagnostic value for EC. The EC prediction model based on these four genes demonstrated high performance (AUC = 0.974 for the training set; AUC = 0.966 for the validation set), and these genes were significantly associated with immune cell infiltration (P < 0.05). CDKN2A, DDA1, LRRC42, and POLB may be common causative genes for OA and early-stage EC, potentially serving as targets for drug intervention.
Keywords: Endometrial cancer; Enrichment analysis; Mendelian randomization; Nomogram; Osteoarthritis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: This study’s data came from a European population via the publicly available GWAS database. Informed consent was obtained from the participants in the original study, which meant that ethics committee approval was not required for this aspect of the research.
Figures







References
-
- Crosbie, E. J. et al. Endometrial cancer. Lancet399, 1412–1428 (2022). - PubMed
-
- Brooks, R. A. et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J. Clin.69, 258–279 (2019). - PubMed
-
- Huvila, J., Pors, J., Thompson, E. F. & Gilks, C. B. Endometrial carcinoma: Molecular subtypes, precursors and the role of pathology in early diagnosis. J. Pathol.253, 355–365 (2021). - PubMed
MeSH terms
Grants and funding
- 2023SFZD02/the Yinchuan Science and Technology Tackling Project
- 2023SFZD02/the Yinchuan Science and Technology Tackling Project
- 2024FRD05067/Special Funds for the Central Government to Guide Local Scientific and Technological Development
- 2024FRD05067/Special Funds for the Central Government to Guide Local Scientific and Technological Development